The first and only study to measure patient-reported TD impact using multiple validated scales
Data on file. Neurocrine Biosciences, Inc.
FOR ADULTS WITH TARDIVE DYSKINESIA (TD)
Achieving REMISSION with INGREZZA
Rapid and robust efficacy at Week 6 with most seeing a response as early as Week 21-3,*
Patients reported improvements in TD impact at Week 242,†
59% of patients reached symptomatic remission at Week 482,4,‡
FOR ADULTS WITH TARDIVE DYSKINESIA (TD)
| ‡ |
Post hoc analysis from open-label KINECT 4. 59% of completers (n/N=61/103) achieved remission at Week 48. Remission defined as ≤1 on each AIMS item 1–7 at Week 48. Results are descriptive. |
HIGHLY EFFECTIVE1,*
More than reductions in TD severity—achieve remission with INGREZZA® (valbenazine) capsules1,4,5,†
SEE REMISSION DATA
PROVEN ACROSS THE WIDEST RANGE OF PATIENTS1,9
EXPLORE DOSING| * |
80 mg significantly reduced AIMS total score by –3.2 (N=79) vs –0.1 (N=76) for placebo from baseline to Week 6 in KINECT 3. P≤0.001 vs placebo; adjusted for multiplicity. At Week 2, ~52% of patients (n/N=41/79) on INGREZZA 80 mg had a ≥2-point decrease from baseline in AIMS total score. |
| † |
Based on patient-reported improvement on the Tardive Dyskinesia Impact Scale from baseline to Week 24 in open-label KINECT-PRO. No prespecified inferential statistical testing was conducted. Results are descriptive. |
| § |
Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and the primary active metabolite of INGREZZA, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes. |
Actor portrayals
FOR ADULTS WITH HUNTINGTON’S DISEASE (HD) CHOREA
Achieving control with INGREZZA
Rapid and robust HD chorea control in a 12-week clinical study, with most seeing a response as early as 2 weeks, and reductions seen through 2 years1,2,10,||
‖≤80 mg significantly reduced TMC score by –4.6 (N=64) vs –1.4 (N=61) for placebo from baseline to end of treatment (average of Week 10 and Week 12 assessments) in KINECT-HD. P<0.0001 vs placebo. At Week 2, 80% (40 mg, n/N=51/64) had a ≥1-point reduction in TMC score. In open-label KINECT-HD2, –5.2 reduction in TMC score at 104 weeks (≤80 mg, n=87).
VIEW HD CHOREA EFFICACY
CONNECT WITH A REPRESENTATIVE
Contact a rep, request INGREZZA samples, sign up for email updates, and more.
CONTACT A REPREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
- Data on file. Neurocrine Biosciences, Inc.
- Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476-484.
- Correll CU, Citrome L, Singer C, et al. Sustained treatment response and global improvements with long-term valbenazine in patients with tardive dyskinesia. J Clin Psychopharmacol. 2024;44(4):353-361.
- Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461.
- Brar S, Vijan A, Scott FL, et al. Pharmacokinetic and pharmacologic characterization of the dihydrotetrabenazine isomers of deutetrabenazine and valbenazine. Clin Pharmacol Drug Dev. 2023;12(4):447-456.
- Skor H, Smith EB, Loewen G, O’Brien CF, Grigoriadis DE, Bozigian H. Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine. Drugs R D. 2017;17(3):449-459.
- Deutetrabenazine [package insert]. Parsippany, NJ: Teva Neuroscience, Inc.
- Stimming EF, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT HD): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2023;22(6)494-504.
- Data on file as of Q3 2024. Neurocrine Biosciences, Inc.